SWP
ACOR

Stratos Wealth Partners’s Acorda Therapeutics ACOR Stock Holding History

Stratos Wealth Partners’s Portfolio ACOR Stock Details ACOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-1
Closed -$4K – 2765
2018
Q1 		$4K Hold
1
– – ﹤0.01% 2709
2017
Q4 		$4K Buy
+1
New +$2.84K ﹤0.01% 2476

Other funds holding ACOR

SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM

Stratos Wealth Partners's ACOR Position: Q2 2018 in Review

Stratos Wealth Partners sold out of Acorda Therapeutics (ACOR) in Q2 2018, closing a stake of 1 share — an estimated $4K sold.

Stratos Wealth Partners first reported a position in ACOR in Q4 2017 and held it in 2 quarters. The position peaked at $4K in Q1 2018. 175 funds tracked by Wall St. Rank hold ACOR as of Q2 2018.

  • Stratos Wealth Partners reported no remaining Acorda Therapeutics position as of Q2 2018 after selling out during the quarter.
  • Stratos Wealth Partners sold 1 Acorda Therapeutics share in Q2 2018, an estimated $4K.
  • Stratos Wealth Partners first reported a position in Acorda Therapeutics in Q4 2017 and held it in 2 quarters.
  • Stratos Wealth Partners's Acorda Therapeutics position peaked at $4K in Q1 2018.
  • 175 funds tracked by Wall St. Rank held Acorda Therapeutics as of Q2 2018.

Based on Stratos Wealth Partners's 13F filing for Q2 2018, filed 13 Aug 2018.